Only Available By Prescription
Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate (ADC) composed of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor. It is indicated for the treatment of adult patients with HER2-positive or HER2-low breast cancer, HER2-positive gastric or gastroesophageal junction adenocarcinoma, and other HER2-expressing solid tumors as approved indications evolve. Enhertu delivers cytotoxic chemotherapy directly to HER2-expressing cancer cells, leveraging targeted delivery to maximize efficacy and minimize off-target toxicity. It has demonstrated significant clinical benefit in patients with heavily pretreated or refractory cancers.
| Fact Table | |
| Formula | Not applicable (antibody-drug conjugate) |
| License | US FDA (2019) |
| Bioavailability | Not applicable (IV only) |
| Legal status | Prescription only |
| Chemical Name | Trastuzumab deruxtecan |
| Elimination half-life | ~6 days |
| Dosage (Strength) | 100 mg lyophilized powder per vial; typical dose: 5.4 mg/kg IV every 3 weeks |
| Pregnancy | Contraindicated – may cause fetal harm |
| Brands | Enhertu |
| Protein binding | Not applicable (monoclonal antibody) |
| PubChem CID | 121304016 |
| MedlinePlus | a621057 |
| ChEBI | N/A |
| ATC code | L01FG03 |
| DrugBank | DB15082 |
| KEGG | D11968 |
| Routes of administration | Intravenous (IV) |
Enhertu is administered via intravenous infusion once every three weeks (21-day cycle). The recommended dose is 5.4 mg/kg for breast cancer and 6.4 mg/kg for gastric cancer, adjusted as needed based on tolerability and clinical response. The first infusion should be given over 90 minutes; if well tolerated, subsequent doses may be infused over 30 minutes. Premedication may be used to prevent infusion reactions. Dose reductions, delays, or discontinuation may be required for adverse events, particularly hematologic toxicity or interstitial lung disease (ILD).
Each Enhertu vial contains:
Enhertu is contraindicated in patients with:
Enhertu carries a boxed warning for interstitial lung disease (ILD) and pneumonitis, which may be fatal. All patients should be monitored for signs of pulmonary toxicity, including cough, dyspnea, and new radiographic findings. Prompt dose interruption and corticosteroid treatment are warranted for suspected ILD. Neutropenia, anemia, and left ventricular dysfunction have been reported and require regular monitoring. Effective contraception is required during treatment and for at least 7 months after the last dose in women of childbearing potential, and for 4 months in male partners. Enhertu is not recommended during pregnancy or breastfeeding.
Common and potential side effects include:
Exceptional Customer Service
We pride ourselves on delivering excellent customer service with as much accessibility as possible.
If you have any questions at all, or would like to place an order, you are encouraged to contact us by toll-free
phone 1-888-904-8467 or email info@canadadrugsdirect.com.
Top Safety and Quality
Canada Drugs Direct employs dedicated, professional licensed pharmacists to ensure that each and every order is reviewed before it is dispensed for the safety and health of our customers. At CanadaDrugsDirect.com, your health is our top priority.
Product Reviews